Amanote Research
Register
Sign In
Human Medicines European Public Assessment Report (EPAR): Olanzapine Glenmark Europe, Olanzapine, Schizophrenia,Bipolar Disorder, Date of Authorisation: 03/12/2009, Revision: 10, Status: Authorised
Case Medical Research
doi 10.31525/cmr-962c2b
Full Text
Open PDF
Abstract
Available in
full text
Date
October 9, 2019
Authors
Unknown
Publisher
Case Journals
Related search
Human Medicines European Public Assessment Report (EPAR): Olazax, Olanzapine, Schizophrenia,Bipolar Disorder, Date of Authorisation: 11/12/2009, Revision: 10, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Aripiprazole Accord, Aripiprazole, Schizophrenia,Bipolar Disorder, Date of Authorisation: 15/11/2015, Revision: 6, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Brilique, Ticagrelor, Peripheral Vascular Diseases,Acute Coronary Syndrome, Date of Authorisation: 03/12/2010, Revision: 12, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Jevtana, Cabazitaxel, Prostatic Neoplasms, Date of Authorisation: 17/03/2011, Revision: 17, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Instanyl, Fentanyl, Pain,Cancer, Date of Authorisation: 20/07/2009, Revision: 21, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Mysimba, Naltrexone / Bupropion, Obesity,Overweight, Date of Authorisation: 26/03/2015, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Levetiracetam Sun, Levetiracetam, Epilepsy, Date of Authorisation: 14/12/2011, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Xyrem, Sodium Oxybate, Cataplexy,Narcolepsy, Date of Authorisation: 13/10/2005, Revision: 29, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Betmiga, Mirabegron, Urinary Bladder, Overactive, Date of Authorisation: 20/12/2012, Revision: 11, Status: Authorised
Case Medical Research
